Replies to post #74933 on Biotech Values

[dewophile]

"The first implies rib monotherapy is not well studied"

it has been studied in terms of viral kinetics and the results were poor - can't really assess effect on relapse when there is a negligible end of treatment response

"rib synergy with the direct anti-virals is not known"

i think there is emerging data on this, but I am not sure how much data there is on synergy with direct antivirals in the absence of interferon

[tony111]

Clark here is a good review article for Ribavirin MOA that answers all your questions



http://www.ncbi.nlm.nih.gov/pubmed/19055642?ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

[DewDiligence]

Ribavirin has weak but well-established efficacy as an HCV anti-replication agent; it typically produces a mean of ~0.8 logs of viral reduction when used as monotherapy. (Source: various CC’s from such companies as GILD, ANDS, VRUS, and IDIX.)